Their average twelve-month price target is $143.82, predicting that the stock has a possible upside of 92.01%. HOLD. Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. © American Consumer News, LLC dba PriceTargets.com ® 2010-2021. Other companies that are similar to Galapagos include UCB, Catalent, Elanco Animal Health, Alnylam Pharmaceuticals, Zai Lab, BioMarin Pharmaceutical, Grifols, Ono Pharmaceutical, Dr. Reddy's Laboratories, Teva Pharmaceutical Industries, Bausch Health Companies, Jazz Pharmaceuticals, Maravai LifeSciences, United Therapeutics and BridgeBio Pharma. At that level they are trading at 6.52% discount to the analyst consensus target price of 0.00. Raymond James raised Galapagos from a market perform rating to an outperform rating and set a $100.00 price objective for the company in a research report on Thursday, February 25th. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Fertilizer producer OCI rises 1.6%, after a price target increase to € 28 by the German investment bank Berenberg … The dark blue line represents the company's actual price. Learn more about MarketBeat. Galapagos NV. Last 30 Days Over the last 30 days, this … Galapagos (NASDAQ:GLPG) Price Target Cut to $117.00 by Analysts at Morgan Stanley. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. (NASDAQ: GLPG) Galapagos Nv's current Earnings Per Share (EPS) is -$5.72. MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. In depth view into Galapagos Price Target Upside (Daily) including historical data from 2008, charts, stats and industry comps. Galapagos N.V. ADR analyst estimates, including GLPG earnings per share estimates and analyst recommendations. RU 中文. The current consensus among 18 investment analysts is to hold stock in Galapagos. Welcome to our new and improved Krieghoff Store! 64,00 €. Toledo exhibits a … The current consensus among 12 TipRanks analysts is for a Hold rating of shares in Galapagos, with an average price target of $101.52. The Galapagos Islands—made up of 13 main islands, 6 smaller islands, and 107 rocks and islets—is well-known for its amazing wildlife. The RSI / MACD and volume showing signs of recovery from recent 60% correction. Get daily stock ideas top-performing Wall Street analysts. In a report issued on April 25, Stifel Nicolaus also maintained a Hold rating on the stock with a $96.00 price target… Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. See today’s analyst top recommended stocks >> The company has a one-year high of $233.14 and a one-year low of $81.37. The lighter blue line represents the stock's consensus price target. changes. Galapagos has an analyst consensus of Moderate Buy, with a price target consensus of $101.77, which is a 41.8% upside from current levels. The analysts price targets … UBS Group reaffirmed a “neutral” rating on shares of Galapagos in a research note on Thursday, February 11th. 326 E 8th St #105, Sioux Falls, SD 57103. The average price target is $143.82, with a high forecast of $290.00 and a low forecast of $94.00. View the latest analyst ratings for GLPG. According to analysts' consensus price target of $143.82, Galapagos has a forecasted upside of 94.3% from its current price of $74.03. The price target was set to $ 129.00. The price will be heading $240 soon. View which stocks are hot on social media with MarketBeat's trending stocks report. It is expected that the biotechnology company runs less risk and also saves costs. In a report issued on May 7, Kepler Capital also maintained a Hold rating on the stock with a EUR79.00 price target. Ratings Network’s free daily newsletter. Find real-time GLPG - Galapagos NV stock quotes, company profile, news and forecasts from CNN Business. The stock has a consensus analyst rating of "Hold." The price target was set to $129.00 → $117.00. Company: Galapagos NV (spons. The average price target represents a 98.29% upside from the last price of $72.53. Bank of America Co. has the lowest price target set, forecasting a price of $94.00 for Galapagos in the next year. Want to see which stocks are moving? 10. All rights reserved. Taking a look at stock we notice that its last check on previous d Whether you are a current investor in Galapagos or are evaluating Galapagos as a potential investment opportunity, we welcome you to contact us should you have any additional questions after reviewing our website. In case the Phase IIb results are convincing and partner AbbVie proceeds to launching Phase III as planned by end 2015, we may raise our Galapagos price target to … Price target in 14 days: 87.849 USD. Galapagos left a big gap behind after tanking hard. 360° Photo 360° Video Photogallery Price List. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Finally, Bank of America raised Galapagos from an “underperform” rating to a “neutral” rating and increased their price target for the company from $93.00 to $94.00 in a … Delayed Data. Nomura has the highest price target set, predicting GLPG will reach $290.00 in the next twelve months. Galapagos Genomics OTC Stock Target Price and Analyst Consensus. ... Average Target Price: 90.99: Number Of … MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Sign-up to receive the latest news and ratings for GLPG and its competitors with Analyst Galapagos currently has 2 sell ratings, 10 hold ratings and 6 buy ratings from Wall Street analysts. Rating by Eliana Merle at Cantor Fitzgerald, Rating by D. Chattopadhyay at HC Wainwright, Rating by Vamil Divan at Credit Suisse Group AG. See today’s analyst top recommended stocks >> InflaRx (IFRX) In a report released yesterday, … The stock gapped due to Gilead buying 10% of Galapagos at $158/share. Rating by James Quigley at JPMorgan Chase & Co. All rights reserved. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Get the hottest stocks to trade every day before the market opens 100% free. Rating by Jason Gerberry at Bank of America Co. Our Accessibility Statement | Terms of Service | Do Not Sell My Information. UBS Group restated a “neutral” rating on shares of Galapagos in a research note on Thursday, February 11th. With the medium-sized funds Galapagos with a profit of 2% in the lead, on the announcement that it will now focus on inflammatory diseases, fibrosis and kidney diseases. Galapagos NV (NASDAQ:GLPG) concluded the trading at $75.04 on Friday, May 07 with a fall of -1.47% from its closing price on previous day.